RNAi Targeting Hepatic AGT to Block RAAS Pathway in Hypertension

“Among individuals with cardiovascular disease or who have high cardiovascular risk with uncontrolled hypertension on multiple antihypertensives, single doses of zilebesiran 300 mg or 600 mg led to respective 5 and 3.3 mm Hg reductions in office systolic blood pressure at 3 months compared with placebo. The statistical significance was not reached. However, subgroup analyses suggest that those on a diuretic may experience greater blood pressure lowering with zilebesiran and it demonstrated an acceptable safety profile with low rates of hyperkalemia, kidney dysfunction and hypotension, which was consistent with prior findings.”

“Every additional pill that somebody takes means that they are less likely to take that pill. If you can even reduce that by one, it may make it easier for patients to take their remaining medications as well.”

“Our study demonstrates that either quarterly or biannual doses of zilebesiran can effectively and safely lower blood pressure in patients with uncontrolled hypertension. It is well known that reductions in systolic blood pressure of greater than or equal to 5 mm Hg are linked to a reduction in cardiovascular risk.”